Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines Micron Biomedical extends Series A to 33+ Million, led by J2 Ventures and GHIC, to accelerate commercialization of needle-free therapeutics and vaccines.

UPDATE - Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles Micron Biomedical won the BARDA Patch Forward competition for it collaboration with Zipcode Bio  to reduce the impact of influenza globally.

Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles Micron Biomedical won the BARDA Patch Forward competition for it collaboration with Zipcode Bio  to reduce the impact of influenza globally.

CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant to Advance Learnings from COVID-19 OSLO, Norway and ATLANTA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) is awarding $3.7 million in new funding to Micron Biomedical to advance...

Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World’s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants Bill & Melinda Gates Foundation grants to accelerate manufacturing of Micron Biomedical’s needle-free technology for measles rubella vaccines